bluebird bio (NASDAQ:BLUE) Price Target Lowered to $3.00 at Wells Fargo & Company

bluebird bio (NASDAQ:BLUE) had its target price reduced by Wells Fargo & Company from $4.00 to $3.00 in a report issued on Wednesday morning, Benzinga reports. They currently have an equal weight rating on the biotechnology company’s stock.

Other research analysts have also recently issued reports about the stock. HSBC dropped their target price on shares of bluebird bio from $2.31 to $1.02 and set a reduce rating on the stock in a report on Tuesday, March 5th. Wedbush cut their price target on bluebird bio from $1.72 to $1.68 and set a neutral rating on the stock in a report on Tuesday, March 19th. StockNews.com raised bluebird bio to a sell rating in a research report on Friday, December 8th. Bank of America reduced their target price on shares of bluebird bio from $12.00 to $5.00 and set a buy rating for the company in a report on Thursday, December 21st. Finally, William Blair reaffirmed a market perform rating on shares of bluebird bio in a research report on Tuesday, January 9th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of Hold and an average target price of $5.87.

bluebird bio Stock Up 13.8 %

Shares of NASDAQ BLUE opened at $1.37 on Wednesday. bluebird bio has a twelve month low of $0.88 and a twelve month high of $5.53. The firm has a market cap of $149.25 million, a PE ratio of -1.84 and a beta of 0.75. The business has a fifty day simple moving average of $1.24 and a two-hundred day simple moving average of $2.28.

Institutional Investors Weigh In On bluebird bio

Large investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company lifted its position in bluebird bio by 6.2% during the 4th quarter. The Manufacturers Life Insurance Company now owns 31,773 shares of the biotechnology company’s stock worth $220,000 after acquiring an additional 1,862 shares during the period. Mariner LLC boosted its position in bluebird bio by 12.8% in the fourth quarter. Mariner LLC now owns 17,972 shares of the biotechnology company’s stock valued at $124,000 after buying an additional 2,043 shares during the last quarter. American International Group Inc. increased its holdings in bluebird bio by 7.1% in the 4th quarter. American International Group Inc. now owns 39,274 shares of the biotechnology company’s stock worth $272,000 after buying an additional 2,609 shares during the period. Captrust Financial Advisors raised its position in bluebird bio by 22.5% during the 3rd quarter. Captrust Financial Advisors now owns 14,679 shares of the biotechnology company’s stock worth $93,000 after buying an additional 2,700 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in bluebird bio by 15.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 23,160 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 3,104 shares during the period. 87.43% of the stock is owned by hedge funds and other institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.